Abstract Number: 030 • 2023 Pediatric Rheumatology Symposium
International Validation of the Total Morbidity Score for Juvenile Localized Scleroderma: 2023 Update
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare condition causing inflammation and fibrosis that may impair health-related quality of life (HRQoL). Recent studies demonstrate extracutaneous…Abstract Number: 2454 • 2019 ACR/ARP Annual Meeting
PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) symptoms and quality of life are core domains for PsA assessment1. The PROMIS Profile29 measures symptoms and quality of life using…Abstract Number: 2456 • 2019 ACR/ARP Annual Meeting
Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis
Background/Purpose: Valuable information on cardiovascular disease outcomes can be obtained from large cohort studies. Such studies often rely on self-reported events, which are best validated…Abstract Number: 292 • 2018 ACR/ARHP Annual Meeting
Derivation of a National Rheumatoid Arthritis Cohort in the Veterans Health Administration and Validation with the Veterans Affairs Rheumatoid Arthritis Registry
Background/Purpose: The Veterans Health Administration health system represents the largest integrated healthcare system in the U.S. and maintains robust administrative and clinical data that can…Abstract Number: 458 • 2018 ACR/ARHP Annual Meeting
Validation of the 2012 Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria Compared to the 1997 Acr Criteria and 2017 Candidate Weighted Criteria for Lupus in Pediatric Patients
Background/Purpose: Different classification criteria for systemic lupus erythematosus (SLE) have been proposed over many years. The most widely used and accepted criteria have been the…Abstract Number: 641 • 2018 ACR/ARHP Annual Meeting
Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis
Background/Purpose: Joint counts are central to the measurement of musculoskeletal disease activity in psoriatic arthritis (PsA). Few studies have addressed whether the three most commonly…Abstract Number: 1406 • 2018 ACR/ARHP Annual Meeting
Longitudinal Construct Validity of the Psaid Individual Items: Can We Eliminate Other Questionnaires If Using the Psaid?
Background/Purpose: The Psoriatic Arthritis Impact of Disease (PsAID) questionnaire is a patient reported measure of disease impact. The 12-item questionnaire has many advantages including demonstrated…Abstract Number: 1606 • 2018 ACR/ARHP Annual Meeting
The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative
Background/Purpose: A psoriatic arthritis (PsA) core domain set to be measured in randomized controlled trials (RCT) and longitudinal observational studies (LOS) was developed by Group…Abstract Number: 2208 • 2018 ACR/ARHP Annual Meeting
Novel Fluorescence Optical Imaging Scoring System of Inflammation in the Hand and Wrist Is in Patients with Rheumatoid Arthritis – Agreement with Ultrasonography and Sensitivity to Change
Background/Purpose: Fluorescence optical imaging (FOI) has been used for assessment of inflammation in the hands and has in several cross sectional studies been compared with…Abstract Number: 2978 • 2018 ACR/ARHP Annual Meeting
Performance of the 2017 European League Against Rheumatism / American College of Rheumatology (EULAR/ACR) Classification Criteria for Adult Idiopathic Inflammatory Myopathies (IIM) in an Australian Cohort
Background/Purpose: EULAR/ACR recently approved classification criteria for idiopathic inflammatory myopathies (IIM) with 93% sensitivity and 88% specificity. An acknowledged limitation of the study is the…Abstract Number: 200 • 2018 ACR/ARHP Annual Meeting
Validation of the Ers-RA Risk Score in a Dutch Population
Background/Purpose: The most frequent cause of death in patients with chronic rheumatoid arthritis (RA) is of cardiovascular (CV) origin. CV risk prediction scores in the…Abstract Number: 226 • 2018 ACR/ARHP Annual Meeting
Representation of Elderly People and Women in Rheumatoid Arthritis and Osteoarthritis Trials: A Systematic Review and Meta-Analysis Comparing Clinical Trials with Population-Based Studies
Background/Purpose: Elderly people (as commonly defined by an age of ≥65 years) and women have been reported to be underrepresented in clinical trials of various…Abstract Number: 352 • 2017 ACR/ARHP Annual Meeting
Psychometric Features of a New Methotrexate (MTX)-Specific Adherence Tool for Use in the Management of Patients with Rheumatoid Arthritis (RA): Preliminary Results from an Online Patient Community
Background/Purpose: F. Hoffmann-La Roche Ltd. and Mapi collaborated to develop a medication adherence measure among RA patients taking MTX—the Methotrexate Experience Questionnaire (MEQ). The MEQ…Abstract Number: 1284 • 2017 ACR/ARHP Annual Meeting
The Localized Scleroderma Quality of Life Instrument (LoSQI): Initial Validation in Pediatric Localized Scleroderma
Background/Purpose: There is a current need to integrate health related quality of life (HRQoL) into outcomes for clinical trials (Chang & Reeve, 2005). For pediatric…Abstract Number: 1805 • 2017 ACR/ARHP Annual Meeting
Construct Validity of RAPID3 for Measurement of Disease Activity in Psoriatic Arthritis
Background/Purpose: The Routine Assessment of Patient Index Data (RAPID3) was developed and validated for rheumatoid arthritis (RA). Little data exist on the use of RAPID3…
- 1
- 2
- 3
- …
- 5
- Next Page »